Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Advertisement
Emily MenendezTesticular, Penile, and Rare Malignancies | September 15, 2023
The AUA released a new amendment to their 2019 guideline for the diagnosis and treatment of early-stage testicular cancer.
Read More
Emily MenendezTesticular, Penile, and Rare Malignancies | September 13, 2023
Newly identified risk factors could be used in future studies on risk-adapted follow-up and treatment strategies.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
Unique characteristics include higher stage at presentation and a more aggressive subsequent clinical course.
David Ambinder, MDTesticular, Penile, and Rare Malignancies | September 1, 2023
It may be time to include RPLND for patients with retroperitoneal disease following treatment for seminoma.
Emily MenendezTesticular, Penile, and Rare Malignancies | August 4, 2023
Is atezolizumab plus radiotherapy or atezolizumab monotherapy more effective for advanced penile cancer?
Emily MenendezTesticular, Penile, and Rare Malignancies | June 26, 2023
As chemotherapy and radiotherapy can negatively impact the QOL of cancer survivors, RPLND offers less burden to patients.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 28, 2023
TC treatment, especially platinum-based chemotherapy, is associated with an increased risk of cardiovascular morbidity.
Emily MenendezTesticular, Penile, and Rare Malignancies | April 7, 2023
The frequency and role of genomic alterations in testicular germ cell tumors is largely unexplored.
Emily MenendezTesticular, Penile, and Rare Malignancies | March 30, 2023
A phase 2 trial examined the safety and efficacy of RPLND as a first-line treatment for early metastatic testicular seminoma.
Emily MenendezTesticular, Penile, and Rare Malignancies | February 27, 2023
Researchers determined the surgical efficacy of RPLND and evaluated recurrence after primary RPLND for CS IIA/IIB seminoma.
Emily MenendezTesticular, Penile, and Rare Malignancies | January 12, 2023
A study analyzed 228 patients with penile cancer who underwent pelvic lymph node treatment with curative intent.
Zachary BessetteTesticular, Penile, and Rare Malignancies | December 27, 2022
Results from a single-institution trial support using surveys to inform comprehensive plans for testicular cancer survivors.
Emily MenendezTesticular, Penile, and Rare Malignancies | December 8, 2022
Researchers reviewed the efficacy of sentinel lymph node biopsy as well as further radical inguinal lymph node dissection.
Leah LawrenceTesticular, Penile, and Rare Malignancies | October 31, 2022
Progression-free survival for stage IIA and stage IIB seminoma was improved with single-dose carboplatin and radiotherapy.
Leah LawrenceTesticular, Penile, and Rare Malignancies | October 4, 2022
Hispanic males had the highest incidence of HPV-associated penile cancers and were diagnosed at later stages.
Leah LawrenceESMO 2022 | September 16, 2022
Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.
Leah LawrenceESMO 2022 | September 16, 2022
A new study has found an association between neurodevelopmental disorders and testicular seminoma.
Leah LawrenceTesticular, Penile, and Rare Malignancies | August 2, 2022
Many TGCT survivors are referred for life-long monitoring due to an increased risk for skin cancer and melanoma.
GU Oncology Now EditorsUrothelial Carcinoma | June 3, 2022
In this paper, we present age-standardized cancer incidence and mortality rates in the Faroe Islands.
GU Oncology Now EditorsRenal Cell Carcinoma | June 3, 2022
RLRN has been widely used in the surgical treatment of renal cancer due to small wound, less bleeding, and rapid recovery.
Advertisement
Advertisement
Advertisement